Pretty good. I think the FDA wanted a bigger trial so they have likely resubmitted the new design. They are still targeting an H2 start. Don thinks there is lots of room for gains from the $200 million market cap. He made a similar comment when we were trading at 50 cents :) They are publishing some epigemetic info later this year and announcing an orphan indication this quarter. Both are catalysts. Otherwise, it seems the slides keep getting more professional so hopefully the right message is getting out there. Bfw